Sygnature Discovery Expands High-Throughput Screening and Translational Oncology

Sygnature Discovery is investing £3 million in new instrumentation and equipment to strengthen its high-throughput screening (HTS) and translational oncology service offerings. Part of the investment will be used to establish internal flow cytometry support for ex-vivo tumor analysis, the company disclosed in a press release dated Dec. 16. Sygnature had added HTS capabilities to its range of identification solutions in November 2019.

“Despite the challenges brought about by the COVID-19 pandemic during 2020, Sygnature Discovery has continued to deliver top quality science to accelerate customers’ drug discovery programmes,” Sygnature CEO and founder, Dr. Simon Hirst, commented in a press release issued on Dec. 16, 2020. “This considerable funding injection will enable Sygnature to provide an even more comprehensive integrated service offering, from hit identification to pre-clinical candidate selection. We have reached an exciting point in our company’s 16-year history, and 2021 will undoubtedly bring even more exciting developments for our business,” he said in the release.